Previous 10 | Next 10 |
home / stock / ipsey / ipsey news
Transaction focused on lead asset Tazverik ® (tazemetostat), a first-in-class EZH2 a inhibitor approved in the U.S. Acquisition to bolster Ipsen’s growing oncology presence and leverage its infrastructure Ipsen to commence all-cash tender offer to...
The clinical-stage oncology company Fusion Pharmaceuticals ( NASDAQ: FUSN ) announced on Thursday that the FDA cleared its Investigational New Drug (IND) applications for [225Ac]-FPI-2059 and the corresponding imaging analogue [111In]-FPI-2058. FPI-2059 is a small molecule...
Ipsen (OTCPK:IPSEY) (OTCPK:IPSEF) said Dysport received positive opinion in Europe for managing urinary incontinence (loss of bladder control) in adults with neurogenic detrusor overactivity (NDO) due to spinal cord injury (SCI) or multiple sclerosis (MS), who are regularly performi...
Submission based on data from the pivotal international Phase III CONTENT clinical program, also recently published in European Urology 1 CONTENT showed that Dysport ® decreased incontinence episodes, detrusor pressure and increased bladder capacity versus placebo...
Ipsen (OTCPK:IPSEY) appointed an investment-services provider to purchase 125K Ipsen S.A. shares or ~0.15% of share capital over a maximum period of three months. The shares purchased under this agreement will be allocated mainly to cover its employee free share-allocation plan. The program w...
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) has appointed an investment-services provider to purchase 125,000 Ipsen S.A. shares, or about 0.15% of the share capital, over a maximum period of three months. The shares purchased under this agreement will be allocated mainly to c...
COSMIC-021 Phase Ib study is evaluating Cabometyx ® (cabozantinib) in combination with atezolizumab in advanced solid tumors, including non-small cell lung cancer New analyses from pivotal Phase III Checkmate -9ER trial further support the superior efficacy of Cabomet...
European Commission (EC) approved Ipsen (OTCPK:IPSEF) (OTCPK:IPSEF) and Exelixis' (EXEL) Cabometyx as a standalone therapy for certain patients with differentiated thyroid cancer (DTC). The EC approval allows for the use of of Cabometyx (cabozantinib) to treat adult patients with lo...
Approval based on data from the COSMIC-311 Phase III trial, in which Cabometyx ® (cabozantinib) demonstrated a 78% reduction in risk of disease progression or death versus placebo 1 This milestone marks the first treatment option to be specifically approved as a secon...
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, publishes its sales performance for the first quarter of 2022. Highlights A strong first-quarter total-sales performance, with growth of 9.6% at CER 1 (12.5% as r...
News, Short Squeeze, Breakout and More Instantly...
Ipsen SA ADR Company Name:
IPSEY Stock Symbol:
OTCMKTS Market:
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases Canada NewsWire Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaboration Following development ...
Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen PR Newswire A Novel TCR Vβ bifunctional selective T cell activator molecule for solid tumor treatment Marengo to receive an associated milestone payment a...
Turnstone Biologics Corp. (TSBX) is expected to report $-0.73 for Q4 2023 Exro Technologies Inc (EXROF) is expected to report for Q4 2023 Boyd Gaming Corporation (BYD) is expected to report $1.43 for Q4 2023 Onto Innovation Inc. (ONTO) is expected to report $0.99 for Q4 2023 Motor...